rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    DARE
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Tuesday's Intraday Session
      Nov 17BenzingaDARESLS
      Dare Bioscience earnings missed by $0.02, revenue fell short of estimates
      Nov 17Investing.comDARE
      Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
      Nov 16Yahoo FinanceDARE
      12 Health Care Stocks Moving In Monday's After-Market Session
      Nov 16BenzingaDARE
      Dare Bioscience shareholders approve stock issuance related to warrant exercise
      Nov 12Investing.comDARE
      Daré Bioscience receives $1.5M grant for contraceptive device
      Oct 30Investing.comDARE
      Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly

      A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston SAN DIEGO, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today announced that Liz Proos, Vice

      Oct 26Yahoo FinanceDARE
      12 Health Care Stocks Moving In Monday's After-Market Session - Biomea Fusion (NASDAQ:BMEA), iTonic Holdi
      Oct 12BenzingaBMEADARE
      Daré Bioscience to present sildenafil cream study data at SMSNA
      Oct 8Investing.comDARE
      Dare Bioscience stock rises after receiving HPV treatment patent
      Sep 28Investing.comDARE
      Daré Bioscience receives U.S. patent for HPV treatment candidate
      Sep 28Investing.comDARE
      Daré Bioscience publishes phase 1 sildenafil cream study data
      Sep 14Investing.comDARE
      Dare Bioscience amends bylaws to lower quorum for shareholder meetings
      Sep 11Investing.comDARE
      Daré Bioscience at H.C. Wainwright conference: turning to sales
      Sep 11Investing.comDARE
      Daré Bioscience receives $908,000 NIH award for preterm birth program
      Aug 31Investing.comDARE
      Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth

      New NIH award will provide approximately $908,000 in year-long support of preclinical development, with potential for an additional future-year grant of...

      Aug 31BarchartDARE
      Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series

      Video webcast now available here SAN DIEGO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech...

      Aug 27BarchartDARE
      Daré Bioscience publishes sildenafil cream study results
      Aug 26Investing.comDARE
      Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society

      Daré’s proprietary formulation of topical sildenafil cream, 3.6% was well tolerated across all evaluated doses in the clinical study, with minimal systemic exposureCompany continues activities necessary to advance its Sildenafil Cream toward the...

      Aug 26BarchartDARE

      This is the newest page. Registered accounts read further back.